<DOC>
	<DOC>NCT02618629</DOC>
	<brief_summary>The aim of this Phase I study is to determine the absorption, metabolism, and excretion of 14C-Z-215 in healthy male subjects following a single oral administration at a therapeutically relevant dose level (20 mg).</brief_summary>
	<brief_title>Mass Balance and Metabolism Study of 14C-Z-215</brief_title>
	<detailed_description />
	<criteria>Any race/ethnic origin Subjects will have a body mass index (BMI) between 18.5 and 30.0 kg/m2 Subjects will have a body weight between 50 and 110 kg Subjects will have given their written informed consent to participate in the study, and to abide by the study restrictions. Subjects who have a significant history of drug allergy, as determined by the Investigator. Subjects who have serum hepatitis or are carriers of the hepatitis B surface antigen (HBsAg) or the hepatitis C antibody. Subjects who have a positive result for the test for human immunodeficiency virus (HIV) antibodies. Subjects who are exposed to radiation as a result of their occupation. Subjects who, in the opinion of the Investigator, should not participate in this study.</criteria>
	<gender>Male</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>